Bio-Rad buys neonate screening test company:
This article was originally published in Clinica
Executive Summary
Bio-Rad Laboratories is buying Perth, Scotland-based Quantase, which develops screening tests for neonates, a market estimated at more than $100 million worldwide, with a 10% growth rate. The deal, for an undisclosed amount, strengthens Hercules, California-based Bio-Rad's position in the genetic screening market. The company notes that genetic screening of newborns is compulsory in the US.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.